Abstract Library

#4588 Spatial transcriptomics identifies Wnt signalling in multifocal ileal neuroendocrine tumours

Introduction: Ileal neuroendocrine tumours (i-NETs) often present with multiple primary tumours (>30-40%). Recent studies showed no shared somatic mutations in multiple primary tumours, highlighting the need to examine the tumour microenvironment in tumorigenesis. The Wnt signalling pathway is crucial for organ stem cell regulation. While the Wnt/β-catenin pathway influences prostate and pancreatic NET/Cs, its role in i-NETs remains unclear.

Conference:

Presenting Author:

Authors: Yogo A, Akanuma N, Kim G, Thirlwell C, Mäkinen N,

Keywords: Wnt Signalling, Spatial Transcriptomics,

#3251 Impact of Wnt signalling on CXCR4 expression and function

Introduction: Loss of Somatostatin Receptor 2 (SSTR2) expression and rising Chemokine Receptor Type 4 (CXCR4) expression are associated with increasing dedifferentiation in Neuroendocrine Tumors (NET). CXCR4 expression is associated with enhanced metastatic and invasive potential and worse prognosis in NET, but might be a theranostic target in NET not sufficiently expressing SSTR2. Likewise, aberrant activation of Wnt/β-catenin signalling may promote a more aggressive phenotype in NET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Rogoll D, Mayer L, Meining A, Kudlich T,

Keywords: neuroendocrine, NET, CXCR4, Wnt, Wnt Signalling, beta-catenin, BON-1, QGP-1,

#3242 Establishment and characterization of a new neuroendocrine carcinoma cell model

Introduction: The development of treatment strategies for neuroendocrine carcinomas (NEC) requires in vitro models expressing NEC–specific targets. The CXC Chemokine Receptor Type 4 (CXCR4), that is expressed in NEC with decreasing differentiation, as well as factors involved in chemotherapy resistance may represent such targets.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Schreiner J, Rogoll D, Werner R, Meining A,

Keywords: neuroendocrine, net, CXCR4, Wnt signalling, beta-catenin, BON-1, QGP-1,

#3222 Impact of Wnt signalling on somatostatin receptor (SSTR) expression and function

Introduction: Somatostatin receptors (SSTR) are expressed by most differentiated neuroendocrine tumors (NET) and are important treatment targets. Loss of SSTR expression is associated with a worse prognosis. Deregulation of Wnt/β-catenin signalling has been demonstrated in NET. Treatment with the Wnt inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) led to growth inhibition in a NET tumor cell line. Other data show an increase in SSTR2 mRNA expression and cellular uptake of radiolabelled octreotide in NET cell lines after incubation with 5-aza-CdR.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Rogoll D, Mayer L, Peschka M, Meining A,

Keywords: NET, Wnt Signalling, somatostatin receptor, BON-1, QGP-1, SSTR,

#3188 mTOR pathway inhibitors differently effect proliferation and gene expression in pancreatic and pulmonary NET cell lines

Introduction: The mammalian target of rapamycin (mTOR) is part of the PI3K/Akt/mTOR signalling pathway which has a central role in the oncogenesis of neuroendocrine tumors (NETs). Everolimus (EVE), an mTOR inhibitor, has shown effective in delaying progression of advanced NETs, but with a limited long-term efficacy, possibly due to a compensatory activation of the PI3K/AKT signalling. BYL719, a PI3K inhibitor, was shown to inhibit growth of several NET cell line models.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Mor-Cohen R

Authors: Mor-Cohen R, Braiman N, Tirosh A,

Keywords: NET cell lines, PI3K/Akt/mTOR signalling, Wnt signalling, everolimus, BYL719,